Obinutuzumab, sold under the brand name Gazyva, is a humanized anti-CD20 monoclonal antibody used as a treatment for cancer. Obinutuzumab binds to an epitope on CD20 that partially overlaps with the epitope recognized by Rituximab. Obinutuzumab has a higher induction rate of antibody dependent cytotoxicity and a higher cytotoxic effect than Rituximab.
Obinutuzumab Biosimilar Antibody
$205.00 – $2,500.00
Obinutuzumab is a humanized immunoglobulin (Ig) G1-kappa monoclonal antibody against human CD20 protein.
Host/Isotype: Human/IgG1
Class: Monoclonal
Immunogen: Human CD20 protein
Production platform: CHO cells
Purification: Affinity chromatography
Storage buffer: PBS, pH 7.2
Storage condition: –20°C
For Research Use Only. Not for use in clinical diagnostics or therapeutics.
Additional information
Antibody Production Scale | 50 ug, 250 ug, 1 mg |
---|---|
Conjugate | None, FITC, HRP, ADC (custom drug) |
You must be logged in to post a review.
Reviews
There are no reviews yet.